MiniMed® Veo™ System

The MiniMed Veo insulin pump

PAGE HIGHLIGHTS

  • Better glucose control is possible with the MiniMed® Veo™

Your pump - your way

Check out accessories for wearing your pump, including pump skins

LEARN MORE

Our MiniMed® Veo™ Insulin Pump system offers:

  • Advanced protection
  • Designed for you
  • Peace of mind

Did you know that better glucose control is possible1,2?

The MiniMed® Veo Insulin Pump and Continuous Glucose Monitoring system with Low Glucose Suspend features innovative technology to more closely mimic the way a healthy pancreas delivers basal insulin to the body. It has been clinically proven to reduce hypoglycemia events, delivering you better glucose control 1,2,3.

Advanced protection

To avoid low blood glucose levels and maintain good glucose control, it is important to know where your glucose levels are and where they are heading. 

Low Glucose Suspend- proven to reduce hypoglycemia3

The MiniMed Veo insulin pump is the only system built with predictive alerts and a  Low Glucose Suspend feature. Low Glucose Suspend (LGS) automatically suspends insulin delivery for up to two hours when your glucose levels fall to a preset level. LGS has been clinically proven to reduce hypoglycemia3, helping to give you the protection you need. 

Some of the benefits of CGM include:

  • Based on your sensor glucose values, the MiniMed Veo can predict when you are approaching low blood glucose levels 30 minutes in advance 
  • CGM allows you to read your glucose levels at any time- keeping you informed around the clock
  • Set alarms to let you know when you are going too high or too low

Designed with you in mind

Diabetes can already be complicated. Your insulin pump system shouldn't be. 

The MiniMed Veo has many features designed with you in mind, including:

  • Insulin Delivery Options
  • Program basal and bolus rates as low as 0.025 units
  • Bolus WizardTM Calculator simplifies your insulin doses by doing the math for you
  • Alert Directed Navigation to reduce the number of steps and button pushes
  • Two different reservoir sizes to meet your insulin needs
  • Missed Bolus Reminder to help prevent post-meal highs 
Simplicity and discretion

The MiniMed Veo comes with the exclusive CONTOUR® NEXT LINK glucose meter from Bayer, designed to wirelessly send glucose readings to your pump.

Make it your own

Choose the colour that fits your personality with 5 colour options available. Plus, you can choose from hundreds of unique skins for your Veo™ insulin pump or design your own. 


Delivering Peace of Mind

The MiniMed® Veo has the flexibility to accommodate your body’s unique requirements with minimum basal and bolus rates of 0.025 units per hour, a max bolus that can be set at any level up to 75 units, and a 1:1 insulin to carb ratio. It also gives you the freedom to set your own routine. Eat, sleep and exercise whenever you like.

REFERENCES

  • 1 Bergenstal RM, Tamborlane WV, Ahmann A, et al. Effectiveness of sensor-augmented insulin-pump therapy in type 1 diabetes. N Engl J Med. 2010;363 (4):311-320
  • 2 Juvenile Diabetes Research Foundation Continuous Glucose Monitoring Study Group. Continuous glucose monitoring and intensive treatment of Type 1 diabetes. N Engl J Med. 2008;359:1464-1476.
  • 3 Bergenstal RM, Klono_ DC, Garg SK. et al. N Engl J Med. June 22, 2013DOI: 10.1056 / NEJMoa1303576

 

This website is intended for use by adults only. The content and all information provided herein is for your informational use only and is not intended to be a substitute for professional medical advice, diagnosis or treatment in any manner. The statements quoted on this website reflect the views and opinions of the patient; Medtronic has not verified any claims and makes no representation as to the accuracy or reliability of the information provided. Statements have been provided by patients of their own free will and Medtronic has had no editorial input into the substance or form of these statements. The patient stories provided are experiences specific to a particular patient. Responses to a particular intervention may vary from patient to patient. Always talk with your physician about diagnosis and treatment information and ensure that you understand and carefully follow that information.

All links to the social media sites are provided for your convenience, and such linkage does not constitute endorsement of those sites by Medtronic, and as such we are not responsible for the content of external web sites, of any comments or responses posted to any web site or social media site by you or anyone else. By submitting any content to any of the social media sites, you understand and acknowledge that this information is available to the public, and that Medtronic may use this information for internal and external promotional purposes. Medtronic shall make reasonable efforts to monitor the content posted on the social media platforms that it manages and Medtronic reserves the right to review, edit and/or delete any comments it deems to be inappropriate (e.g. offensive comments, spam) on those Medtronic platforms.

© 2014 Medtronic of Canada, Ltd. All Rights Reserved. No part of this website may be reproduced or utilized in any form or by any means without permission from Medtronic International Trading Sarl.

All trademarks are the property of their respective owners. MiniMed, Paradigm and Medtronic CareLink are registered trademarks and Veo, Bolus Wizard, Guardian, Enlite are trademarks of Medtronic of Canada Ltd. CONTOUR is a trademark of Bayer Healthcare LLC.

1. Bergenstal RM, Tamborlane WV, Ahmann A, et al. Effectiveness of sensor-augmented insulin-pump therapy in type 1 diabetes. N Engl J Med. 2010;363(4):311-320
2. Juvenile Diabetes Research Foundation Continuous Glucose Monitoring Study Group. Continuous glucose monitoring and intensive treatment of Type 1 diabetes. N Engl J Med. 2008;359:1464-1476.
3. Corriveau EA, Durso PJ, Kaufman ED, et coll. Effect of CareLink ®, an internet based insulin pump monitoring system, on glycemic control in rural and urban children with type 1 diabetes mellitus. Pediatr Diabetes. 2008;9(Partii):360-366.
4.  Bergenstal RM, Klonoff DC, Garg SK. E t al. N Engl J Med. June 22, 2013DOI: 10.1056 / NEJMoa1303576
5. Data on file from only voluntary CareLink Personal Paradigm Veo Uploads available from May 1, 2011 to Sep 9, 2014 evaluated. Presented at Medtronic EASD CGM roundtable.
*2015 proprietary market research. Data on file.
** Terms and conditions apply.

Email